Although the mechanisms of TKI resistance in NSCLC patients is not fully explored, there is evidence that receptor tyrosine kinases (RTKs), like MET and the MERTK ligand GAS6, may play a role [24,25]. The gene discussed is GAS6; the disease is non-small cell lung carcinoma.